SAN CARLOS, Calif., June 05, 2023 Allakos Inc. , a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved. | June 5, 2023
Allakos Inc. (NASDAQ:ALLK – Get Rating) has been given a consensus rating of “Moderate Buy” by the six analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The […]
Jefferies Financial Group upgraded shares of Allakos (NASDAQ:ALLK – Get Rating) from a hold rating to a buy rating in a research note released on Thursday, The Fly reports. Jefferies Financial Group currently has $9.00 price target on the stock, up from their prior price target of $6.00. Other analysts have also issued research reports […]
Jefferies Financial Group upgraded shares of Allakos (NASDAQ:ALLK – Get Rating) from a hold rating to a buy rating in a research note released on Thursday morning, The Fly reports. Jefferies Financial Group currently has $9.00 price target on the stock, up from their prior price target of $6.00. Several other equities analysts have also […]
Analysts’ updated eps estimates for Thursday, May 11th: Allakos (NASDAQ:ALLK) was upgraded by analysts at Jefferies Financial Group Inc. from a hold rating to a buy rating. Converge Technology Solutions (OTCMKTS:CTSDF) was downgraded by analysts at BMO Capital Markets from an outperform rating to a market perform rating. Derwent London (OTCMKTS:DWVYF) was downgraded by analysts […]